This week, the FDA will decide whether to approve Vertex Pharmaceuticals' non-opioid painkiller. Vertex believes pain could ...

Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...

A novel once-daily drug showed a comparable efficacy and safety profile as the standard-of-care drug in patients with cystic ...

The startups are the fourth and fifth drugmakers to file for initial stock sales since late December — the most IPO activity ...

While some analysts expect the 2025 IPO market to be relatively cool in the near-term, others anticipate more bids than in ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Orphan drugs offer critical treatment options for rare diseases, improving quality of life for underserved patients and ...

Some people with cystic fibrosis still do not have access to the life-changing modulator therapy drugs, despite wider EMA ...

The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...

K grant to accelerate development of Glox Therapeutics' novel precision antibiotics targeting AMR lung infections in people ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.